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Spontaneously Reported Hepatic Adverse Drug Events in Korea: 
Multicenter Study
Hepatic adverse drug reactions (ADRs) to certain drugs may differ within each country, 
reflecting different patterns of prescription, socioeconomic status, and culture. The 
purpose of this study was to assess the suspected cause of hepatic ADRs using the 
spontaneously reported pharmacovigilance data from Korea. A total of 9,360 
spontaneously reported adverse drug events (ADEs) from nine Pharmacovigilance Centers 
were analyzed. Risk of hepatic ADEs  was assessed by calculating the reporting odds ratio 
(ROR). Of the 9,360 cases, 567 hepatic ADEs were reported. The most frequently 
prescribed drug classes inducing hepatic ADEs were anti-tuberculotics, cephalosporins, 
valproic acids, penicillins, quinolones, non-steroidal anti-inflammatory drugs (NSAIDs), 
anti-viral agents, and statins. ROR values were especially high in anti-tuberculosis drugs, 
systemic antifungal drugs for systemic use, anti-epileptics, propylthiouracil, and herbal 
medicines. Underlying diseases such as tuberculosis (6.9% vs 0.9%), pneumonia (4.9% vs 
1.7%), intracranial injury including skull fracture (4.5% vs 0.9%), HIV (3.4% vs 0.4%), 
subarachnoid hemorrhage (2.8% vs 0.5%), and osteoporosis (2.4% vs 1.4%) were 
significantly more common in hepatic ADE group. In conclusion, anti-infective drugs, 
anti-epileptics, NSAIDs and statins are the most common suspects of the spontaneously 
reported hepatic ADEs, in Korea. Careful monitoring for such reactions is needed for the 
prescription of these drugs.
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INTRODUCTION
Drug-induced liver diseases are important adverse drug reac-
tions (ADRs) and impart significant medical burdens to pa-
tients, doctors, and pharmaceutical companies. Drugs are im-
portant causes of` acute hepatitis, an extreme ADR, and are re-
sponsible for approximately 15.6% of liver transplantation for 
acute liver failure (1). The true incidence of hepatic ADRs is dif-
ficult to determine, but is reported to be between 1 in 10,000 
and 1 in 100,000 patients (2). Drug-induced ADRs to the liver is 
the single most important reason for drug withdrawal from the 
market and can halt drug development (3, 4). Post-market sur-
veillance using a reporting system is therefore especially impor-
tant for hepatic ADRs. 
 Clinical studies have shown marked differences in such caus-
ative drugs. In Korea (5-7) and East Asian countries (8), herbal 
medicines, antibiotics, and non-steroidal anti-inflammatory 
drugs (NSAIDs) have been reported as major causative agents 
of hepatic ADRs. In Western countries and the United States, 
antibiotics, acetaminophen, NSAIDs, anti-tuberculosis agents, 
and central nervous system agents were recognized as major 
culprits (1, 9, 10). These studies were primarily performed by 
experienced hepatologists with hospitalized patients suffering 
from severe drug-induced liver disease. These studies may have 
limitations due to selection biases, including more serious he-
patic ADRs, and focused on the general features of drug-induced 
liver diseases.
 Since 2006, spontaneous reporting in pharmacovigilance 
systems has been established successfully in Korea (11), and 
the collected data were analyzed. Spontaneous ADR reporting 
systems have weak points such as inaccuracy of ADR diagnosis, 
underreporting, and an inability to obtain ADR incidences (12, 
13), but is useful for signal detections of hepatic ADRs, and the 
reporting odds ratio has been recognized as a useful tool for de-
tection of disproportionally reported drugs for a ADEs (14, 15). 
However, data from spontaneous reporting pharmacovigilance 
programs may allow evaluation of the general aspects of hepat-
ic ADRs. In this study, we evaluated the drugs suspected as the 
causative drugs of hepatic ADRs and measured the reporting 
odds ratio (ROR) values using the spontaneous reporting phar-
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macovigilance data from nine Regional Pharmacovigilance Cen-
ters in Korea.
 
MATERIALS AND METHODS 
For this study, 9,360 cases of adverse drug events (ADEs) were 
collected from nine Regional Pharmacovigilance Centers in 
Korea from January 2007 to December 2008. Each regional cen-
ter collected ADEs from both general hospitals (90%) and gen-
eral practitioners from private clinics or pharmacies (10%). The 
method of reporting ADEs was a voluntary system that relied 
on written reports submitted via fax, website, or electrical med-
ical recording systems generated by physicians, pharmacists, 
and nurses. ADEs were coded using the World Health Organi-
zation (WHO) Adverse Reaction Terminology (ART) (16), which 
consists of four components: preferred terms, high-level terms, 
systemic organ class, and included terms. We evaluated the cau-
sality of these ADE cases according to WHO Uppsala Monitor-
ing Center (UMC) criteria (17) at each regional center. WHO-
UMC criteria classify ADEs as certain, probable, possible, un-
likely, conditional and unassessable. The causality was assessed 
by the physicians majored in Internal Medicine. Once causality 
was assessed, the ADRs were characterized by severity as either 
serious or non-serious (17). The serious category included life-
threatening, disabling, or permanent disabilities or prolonged 
hospitalization. The ADRs were further classified by the type of 
reactions (17). Type A reactions were usually dose-related, pre-
dictable, preventable, and rarely life threatening, while Type B 
reactions were not dose-related and were idiosyncratic, unpre-
ventable, and potentially life threatening. Type C reactions were 
both dose- and time-related. Hepatic ADRs were considered 
when the levels of serum alanine aminotransferase, alkaline 
phosphatase, or total bilirubin were increased to at least 2-fold 
higher than baseline without other plausible causes. All data of 
reported ADE are submitted to central office of the pharmaco-
vigilance centers.
 Descriptive statistics were performed to assess the ADR cases. 
An association between drugs and hepatic ADRs was assessed 
by comparing hepatic ADRs with non-hepatic ADRs and calcu-
lating the ROR as a measure of disproportion. Comparisons of 
these two groups were performed using an independent t test 
or chi-square test. 
 ROR values were calculated using the equation shown below. 
The basic assumption is that no relationship exists between the 
reported suspected ADR and the suspected drug, and the mea-
sure of disproportionality can be calculated by means of the Pois-
son probability (14, 15). 
Ethics statement
The study protocol was reviewed by the institutional review board 
of Severance Hospital Clinical Trials Center (IRB No. 4-2011-
0372) and got permission for exemption. 
RESULTS
Causality assessment using WHO-UMC classified the 9,360 
cases to certain (n = 942, 10.1%), probable (n = 3,444, 36.8%), 
possible (n = 4,252, 45.4%), unlikely (n = 661, 7.1%), and unac-
cessable (n = 61, 0.6%) groups. Hepatic ADRs comprised 6.1% 
(567 cases) of all enrolled ADRs (9,360 cases). Thirty-eight per-
cent (n = 215) of hepatic ADE patients also had non-hepatic 
ADEs. WHO-UMC causality assessment of hepatic ADEs was 
as like; certain (6.9%), probable (22.6%), possible (60.7%), un-
likely (9.5%) and unassessable (0.03%). There were no differ-
ences in age or gender of patients with hepatic or non-hepatic 
ADEs (Table 1). Enrolled subjects had an average of 1.7 under-
lying diseases that required treatment, and the patterns of these 
    Reports with   Reports without 
    hepatic ADE    hepatic ADE
Reports with the suspected drug                a                     b
All other drugs                             c                     d
   ROR = (a/c)/(b/d) = ad/bc
   95% confidence interval of ROR = e ln(ROR) ± 1.96 √(1/a+1/b+1/c+1/d)
   All calculations were performed using the statistical software 
package SPSS 15.0 (Statistical Package for the Social Sciences, 
Chicago, IL, USA).
Table 1. Clinical characteristics of the patients with spontaneously reported adverse drug reactions (ADR) 
Characteristics Hepatic ADRs (n = 567) Non-hepatic ADRs (n = 8,793) ROR (95% CI) P value
Mean age (yr) 50.2 ± 17.5 49.9 ± 18.9 0.672
Gender (M:F) 259:308 4,172:4,621 0.414
Seriousness of ADRs 75 (13.2%) 602 (6.8%) 2.1 (1.6-2.7) < 0.001
Underlying diseases (%)
   Tuberculosis
   Pneumonia 
   Intracranial injury & skull fracture
   HIV 
   Subarachnoid hemorrhage 
   Osteoporosis 
 
6.9
4.9
4.5
3.4
2.8
2.4
 
0.9
1.7
0.9
0.4
0.5
1.4
 
  8.4 (5.5-12.9)
3.0 (1.9-4.7)
5.3 (3.2-8.7)
  9.1 (5.0-16.6)
  6.4 (3.4-11.9)
1.8 (1.0-3.3)
 
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.049
ROR, reporting odds ratio; HIV, human immunodeficiency virus.
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underlying diseases differed between hepatic and non-hepatic 
ADR groups. Patients with hepatic ADEs suffered more frequent-
ly with tuberculosis (6.9%), pneumonia (4.9%), intracranial in-
jury including skull fracture (4.5%), HIV (3.4%), subarachnoid 
hemorrhage (2.8%), and osteoporosis (2.4%). Patients with he-
patic ADEs experienced serious ADEs more frequently than pa-
tients in the other groups because of liver disease (13.2% vs 6.8%). 
ADEs were classified into WHO-ART categories and are shown 
in Table 2. The suspected drugs for hepatic ADEs were classi-
fied according to the WHO Anatomical Therapeutic Chemical 
(ATC) code. Anti-infectives (code-J, 55.6%), nervous system drugs 
(code-N, 16.6%) musculoskeletal system drugs (code-M, 6.0%) 
and cardiovascular system drugs (code-C, 4.4%) comprised the 
majority of causative drugs (Table 3). 
 Each culprit drug was analyzed in detail (Table 4). The anti-
tuberculosis drugs were the most common triggers for hepatic 
toxicity: isoniazid (5.5%), rifampicin (4.9%), and pyrazinamide 
(4.6%). Their mean relative ROR for hepatic ADRs compared 
with non-hepatic ADRs was 5.1 (4.1-6.4, P < 0.001). Although 
the cephalosporins (9.5%), penicillins (5.1%), quinolones (5.1%), 
carbapenems (1.6%), and glycopeptide antibiotics (2.3%) also 
caused hepatic ADRs, their ROR values were between 0.7 and 
1.9. Only one case of hepatic ADRs induced by amoxillin/clavu-
lanic acid was reported in this study. NSAIDs were important 
Table 2. Preferred criteria of the WHO-Adverse Reaction Terminology for hepatic ADE 
reports
Hepatic ADR WHO-ART Number Percent (%)
Hepatic enzyme levels increased* 266 46.9
Bilirubin levels increased† 21 3.7
Hepatitis 93 16.4
Hepatic function abnormal 64 11.3
Hepatic disease 5 0.9
Hepatotoxicity 3 0.5
Unknown 115 20.3
Total 567 100
*Alanine aminotransferase level was increased at least more than two-fold compared 
to baseline; †total bilirubin level was increased at least more than two-fold compared 
to baseline. ADE, adverse drug events; WHO-ART, World Health Organization-Adverse 
Reaction Terminology.
Table 3. WHO-Anatomical Therapeutic Chemical codes of drugs causing hepatic ADRs
Drugs or system(s) treated (ATC code)
Hepatic ADR 
frequency (%)
Total ADR  
frequency (%)
Anti-infectives for systemic use (J) 315 (55.6) 3,173 (33.9)
Nervous system (N) 94 (16.6) 2,052 (21.9)
Musculoskeletal system (M) 34 (6.0) 801 (8.6)
Cardiovascular system (C) 25 (4.4) 466 (5.0)
Anti-neoplastics and immune modulators (L) 20 (3.5) 344 (3.7)
Alimentary tract and metabolism (A) 16 (2.8) 745 (8.0)
Blood and blood-forming organs (B) 13 (2.3) 244 (2.6)
Respiratory system (R) 10 (1.8) 434 (4.6)
Systemic hormonal preparation (H) 10 (1.8) 126 (1.3)
Herbal medicines 3 (0.5) 8 (0.1)
Genitourinary system (G) 3 (0.5) 78 (0.8)
Anti-parasitic/insecticides (P) 1 (0.2) 11 (0.1)
Dermatologic (D) 0 17 (0.2)
Sensory organs (S) 0 9 (0.1)
Various (V) 6 (1.1) 683 (7.3)
Unidentified medicines 17 (3.0) 169 (1.8)
Total 567 (100) 9,360 (100)
Table 4. Causative drugs and their reporting odd ratios (RORs) for hepatic ADRs
Drugs
Hepatic  
ADR (%) 
[n = 567]
Non-hepatic 
ADR (%)  
[n = 8,793]
ROR  
(95% CI)
 P  value
Anti-tuberculosis agents
   Rifampicin
   Isoniazid
   Pyrazinamide
   Ethambutol
   Aminosalicylic acid
   Protionamide
112 (19.8)
28 (4.9)
31 (5.5)
26 (4.6)
17 (3.0)
4 (0.7)
3 (0.5)
405 (4.6)
118 (1.3)
96 (1.1)
69 (0.8)
91 (1.0)
7 (0.1)
9 (0.1)
5.1 (4.1-6.4)
3.8 (2.5-5.8)
5.2 (3.5-7.9)
6.1 (3.8-9.6)
3.0 (1.7-5.0)
8.9 (2.6-30.6)
5.2 (1.4-19.2)
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.003
0.032
Cephalosporins 54 (9.5) 885 (10.1) 0.9 (0.7-1.3) 0.678
Carbapenems 9 (1.6) 88 (1.0) 1.6 (0.8-3.2) 0.181
Penicillins
   Amoxacillin/clavulanate
   Piperacillin/tazobactam
29 (5.1)
1 (0.2)
20 (3.5)
322 (3.7)
92 (1.0)
110 (1.3)
1.4 (1.0-2.1)
0.2 (0.0-1.2)
2.9 (1.8-4.7)
0.078
0.043
< 0.001
Quinolones 29 (5.1) 248 (2.8) 1.9 (1.3-2.8) 0.002
Sulphonamides 2 (0.4) 34 (0.4) 0.9 (0.2-3.8) 0.898
Glycopeptide antibiotics 13 (2.3) 305 (3.5) 0.7 (0.4-1.1) 0.151
Aminoglycosides 5 (0.9) 64 (0.7) 1.2 (0.5-3.0) 0.610
Macrolides 6 (1.1) 98 (1.1) 0.9 (0.4-2.2) 0.901
Clindamycin 6 (1.1) 29 (0.3) 3.2 (1.3-7.8) 0.017
Antimycotics 
   Amphotericin B
   Fluconazole
   Itraconazole
6 (1.1)
1 (0.2)
2 (0.4)
3 (0.5)
25 (0.2)
10 (0.1)
6 (0.1)
4 (< 0.1)
3.8 (1.5-9.2)
1.6 (0.2-12.1)
5.2 (1.0-25.7)
11.7 (2.6-52.3)
0.010
0.673
0.025
0.006
Antivirals
   Protease inhibitors
   Atazanavir
   Nucleoside RT inhibitors
12 (2.1)
7 (1.7)
7 (1.2)
4 (0.7)
109 (1.2)
22 (0.3)
6 (0.1)
26 (0.3)
1.7 (0.9-3.1)
5.0 (2.1-11.7)
18.3 (6.1-54.7)
2.4 (0.8-6.9) 
0.073
0.001
< 0.001
0.105
Anti-epileptics
   Valproic acid
   Topiramate
   Phenytoin
   Carbamazepine
   Lamotrigine 
   Gabapentin 
55 (9.7)
33 (5.8)
8 (1.4)
1 (0.2)
6 (1.1)
2 (0.4)
2 (0.4)
281 (3.2)
81 (0.9)
15 (0.2)
28 (0.3)
50 (0.6)
32 (0.4)
24 (0.3)
3.3 (2.4-4.4)
6.6 (4.4-10.1)
8.4 (3.5-19.8)
0.6 (0.1-4.1)
1.9 (0.8-4.4)
1.0 (0.2-4.1)
1.3 (0.3-5.5)
< 0.001
< 0.001
< 0.001
0.555
0.151
0.966
0.670
Anti-psychotics 7 (1.2) 95 (1.1) 1.1 (0.5-2.5) 0.732
NSAIDs
   Salicylates
   Anilides 
      Acetaminophen
      Acetaminophen/
         tramadol
      Propacetamol
   Acetic acid derivatives
   Propionic acid derivates
   Coxibs
   Nabumetone
24 (4.2)
2 (0.4)
13 (2.3) 
1 (0.2)
7 (1.2)
5 (0.9)
4 (0.7)
4 (0.7)
1 (0.2)
10 (1.8)
494 (5.6)
152 (1.7)
209 (2.4)
71 (0.8)
126 (1.4)
12 (0.1)
182 (2.1)
177 (2.0)
17 (0.2)
36 (0.4)
0.7(0.5-1.1)
0.2 (0.1-0.8)
1.0 (0.5-1.7)
0.2 (0.0-1.6)
0.9 (0.4-1.8)
6.5 (2.3-18.5)
0.3 (0.1-0.9)
0.3 (0.1-0.9)
0.9 (0.1-6.9)
4.4 (2.2-8.8)
0.162
0.013
0.898
0.095
0.699
0.003
0.024
0.028
0.929
< 0.001
Allopurinol 4 (0.7) 33 (0.4) 1.9 (0.7-5.3) 0.282
Antineoplastics and 
   immune modulator
20 (3.5) 324 (3.7) 1.0 (0.6-1.5) 0.847
Propylthiouracil 2 (0.4) 2 (< 0.1) 15.6 (2.2-110.7) < 0.001
Lipid-modifying agents
   HMG CoA inhibitors
   Fibrates
10 (1.8)
7 (1.2)
2 (0.4)
59 (0.7)
36 (0.4)
9 (0.1)
2.7 (1.4-5.2)
3.0 (1.3-6.9)
3.5 (0.7-16.0)
0.008
0.014
0.140
Herbal medicines 3 (0.5) 5 (0.1) 9.3 (2.2-39.2) 0.010
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causes of hepatic ADRs with different ROR values, comprising 
4.2% of all drugs causing hepatic ADRs. Six cases of hepatic ADEs 
associated with systemic anti-fungal agents (1 case by ampho-
tericin, 2 cases by fluconazole and 3 cases by itraconzole) were 
reported; but ROR values for fluconazole and itraconazole are 
especially higher (5.2-11.7). Antiviral agents were also emerging 
as the important causes of hepatic ADEs. Seven cases of hepatic 
ADE associated with atazanavir, protease inhibitor used for HIV 
infection, were reported (ROR 5.0, P < 0.001).
 Anti-epileptics, such as valproic acid (5.8%, ROR 6.6, P <  
0.001), were also major culprits. The mean overall ROR of NSAIDs 
was 0.7 (0.5-1.1 ADRs by anilides [acetaminophen, a mixture 
including acetaminophen, and propacetamol], which included 
2.3% of hepatic ADRs with low RORs [1.0]). Nabumetone com-
prised 1.8% of hepatic ADRs and had the highest ROR values 
(4.4, P < 0.001) among all the NSAIDs. In this study, only two 
cases of hepatic ADEs associated with propylthiouracil were re-
ported, but their ROR value is especially high to 15.6 (P < 0.001). 
Lipid-modifying agents, such as statins (ROR 3.0 P = 0.014), were 
also frequently associated with hepatic ADEs. Herbal medicines 
have been reported as the important causes of hepatic ADRs in 
Korea and other Asian countries. But in this study, herbal medi-
cines comprised only 0.5% of hepatic ADRs with high mean 
ROR values (9.3, P = 0.010). However, we could not identify the 
details of the herbal medicines prescribed.
 
DISCUSSION
This is the first study of hepatic ADRs based on the spontaneous 
reporting program in Korea. Our spontaneous reporting system 
collected data from doctors, nurses, and pharmacists working 
in general hospitals or private clinics. Spontaneous reporting 
systems are important for the surveillance hepatic ADRs but 
have several weak points. However, the incidence of ADRs can-
not be estimated from the data of spontaneous ADR monitor-
ing systems. Underreporting is a well-known problem in spon-
taneous reporting (13), and as denominators were unknown, 
our data cannot be used for estimations of hepatic ADR inci-
dence. Our program for pharmacovigilance is mainly designed 
for the monitoring the ADEs inevitably occurred by adequately 
prescribed in hospitals and private clinics. The program did not 
include medication errors or drug abuse, and professionals for 
oriental medicine are not participating to the program. These 
features imperatively affected the results. The hepatotoxicity of 
drugs may be related to overdose of medication. In this study, 
the patients were prescribed to the therapeutic dosages. The 
major suspected drugs for hepatic ADRs in this study are anti-
microbials, central nervous system drugs, and NSAIDs. These 
results are similar to reports from the United States and Europe 
(10) but differ from previous studies done in Korea (5-7) and 
East Asia (8). We hypothesize that this may be the reason why 
the incidence of hepatic ADRs after treatment with herbal med-
icines is lower than the incidences found in other Asian studies 
(5-8). Herbal medicines comprise 0.5% of suspected hepatic 
ADRs with high ROR values for hepatic ADR in this study, sug-
gesting that herbal medications could be an important cause of 
hepatic ADRs in Korea, where the oriental medicine is popular 
(18). WHO and the Uppsala Monitoring Centre have emphasized 
the monitoring of herbal products for coordinated regional phar-
macovigilance centers (19). We think that the activity is espe-
cially important in Korea, and now extend our activities to cover 
the herbal medicines prescribed by oriental medicine profes-
sionals and herbal foods purchased from market. There is an-
other point that should be considered. This pharmacovigilance 
program started in 2006 from the educating general hospitals 
hosting the Regional Pharmacovigilance Centers and is now 
spreading to general practitioners in private clinics or pharma-
cies. The number of reported ADEs from private clinics or phar-
macies is increasing, but the portion is still minor. About 90% of 
the reported ADE cases came from the 9 educating general hos-
pitals, and this feature may explain the low incidence of ADEs in 
suspect of amoxicillin/clavulanic acid. Contrary to other reports 
(9), only one case of hepatic ADR induced by amoxicillin/clavu-
lanic acid and another case due to phenytoin were reported in 
this study. Amoxicillin/clavulanic acid is still the first line anti-
biotics for acute sinusitis and other infectious diseases for gen-
eral practitioners in Korea. However multi-drugs resistant Strep-
tococcus pneumoniae or methicillin resistance Staphylococcus 
aureus are big problems for the community acquired infections 
in Korea and prescriptions of anti-streptococcal quinolones or 
other classes of antibiotics are increasing instead of amoxicil-
lin/clavulanic acid (20). Phenytoin is a well known culprit for 
hepatic ADRs. In Korea, phenytoin rarely prescribed due to var-
ious ADRs and drug interactions, in addition to hepatic ADRs. 
Instead of phenytoin, other newly developed safe and effective 
anti-epileptics are popularly used.
 In Western countries and the United States, acetaminophen 
is a common cause of dose related drug-induced hepatic inju-
ry: it is the most common cause of liver transplantation for acute 
liver failure in the United States (1, 21). Acetaminophen over-
dose is often used for suicide attempts in Western societies, which 
is not a familiar concept in Korea. While acetaminophen use is 
popular in Korea, only a few cases of acetaminophen-induced 
hepatitis were reported in this study. This result may be due to 
the characteristics of the enrolled cases, which are primarily 
from the general hospital with adequately regulated prescrip-
tions and a pharmacovigilance program that does not include 
patient drug abuse.
 There is another limitation to this study. Aithal et al. (22) re-
ported that approximately 50% of spontaneously reported he-
patic ADRs are misdiagnosed. We enrolled nine Regional Phar-
macovigilance Centers, but their activities, experiences, capa-
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bilities and organization may differ among them. For diagnosis 
of hepatic ADRs, underlying causes of hepatitis such as viral 
hepatitis, autoimmune hepatitis, alcoholic liver disease, steato-
hepatitis, and other metabolic diseases should be excluded (23). 
The enrolled cases were from spontaneous reports of both non-
hepatologist and hepatologist physicians, pharmacists, and 
nurses. Clinical data were not detailed in the reports, and we 
could not evaluate the clinical courses and features of enrolled 
patients. Hepatic ADRs are usually classified as hepatocellular, 
mixed, and cholestatic (3). We could not classify hepatic ADRs 
with this classification scheme, but merely indicated the regis-
tered WHO-ART coding, which is the official coding system for 
the pharmacovigilance program for hepatic ADRs in this study 
(16). We also used WHO-UMC criteria for causality assessment. 
The criteria classify ADEs as certain, probable, possible, unlike-
ly, conditional and unassessable. In this study, only 6.9% and 
22.6% of hepatic ADRs are certain or probable. This means that 
significant portion of the hepatic ADRs in this study may not be 
actually the cause of hepatitis. Some antibiotics with very low 
risk of hepatotoxicities, such as glycopeptides antibiotics and 
aminoglycosides were reported as the suspects, but their ROR 
values are 0.7 and 1.2, respectively, and possibility of misdiag-
nosis could not be excluded.
 Many investigators have used the Russel Uclaf Causality As-
sessment Model (RUCAM) for assessing hepatic ADRs (24, 25), 
but there are limitations in clinical use as it has lower reliability 
(26). WHO-UMC criteria are globally accepted causality assess-
ment criteria for ADRs in general. Compared to RUCAM, WHO-
UMC criteria may have some weak points in subjectivity and 
limited reproducibility. Many criteria for causality assessment 
are currently available, but they share key components for assess-
ment, such as chronological relationship between administra-
tion of drug and onset of ADRs, exclusion of other possible causes 
not involving drugs, previous information on similar events at-
tributed to the suspected drugs, improvement after discontinu-
ation of causative drugs, and aggravation or reappearance of 
ADR by re-administration of causative drugs. However, our data 
may have advantages for obtaining the general aspects of drugs 
that cause hepatic ADRs in Korea compared with previous stud-
ies done by hepatologists with patients admitted due to hepatic 
ADRs. This study included cases of hepatic ADRs with various 
severities.
 Anti-infective drugs were the most common cause of hepatic 
ADRs in this study. However, marked differences in ROR values 
were found among the anti-infectives. As is known, anti-tuber-
culosis and anti-fungal agents have high ROR values. In this 
study, anti-viral agents were also emerging as the important 
causes of hepatic ADRs. In Korea, the prevalence of tuberculo-
sis is very high and the prevalence of HIV infection is soaring, 
and our data might reflect the situation. Cephalosporins are 
also important causes of hepatic ADRs, as they are commonly 
prescribed in Korea. However, their ROR values were not ele-
vated compared with the incidence of non-hepatic ADRs due 
to cephalosporins. 
 Marked differences in underlying diseases requiring treat-
ment were found in our study. Patients with hepatic ADRs more 
frequently suffered from tuberculosis, pneumonia, brain injury 
or subarachnoid hemorrhage, and HIV infection. The differences 
may reflect the drugs that cause hepatic ADRs. Infection with 
HIV is generally considered a predisposition to hepatic ADRs. 
HIV infection is a well-known risk factor for drug allergy; and 
the relationship between HIV and hepatic ADRs is therefore 
apparent (27). It is unclear whether HIV infection is related to 
the development of hepatic ADRs, but it is not surprising that 
HIV-infected patients are susceptible to hepatic ADRs, as they 
commonly are treated with drugs well known to cause hepatic 
ADRs such as isoniazid, rifampicin, trimethoprim-sulfamethox-
azole, NSAIDs, and antiviral agents (28).
 In this study, there were no differences in ages or gender ratios 
between hepatic and non-hepatic ADR groups. Age and gender 
have been previously regarded as risk factors for hepatic ADRs. 
Traditionally, patients at advanced ages and women were as-
sumed to be susceptible groups (7, 21), but this assumption be-
comes now controversial. There was no difference in age or gen-
der between hepatic or non-hepatic ADR groups in this study. 
Our result was consistent with that of Shapiro and Lewis (29), 
which reviewed published data and did not find any evidence 
that patients at advanced ages or women were more suscepti-
ble to hepatic ADRs caused by any drug. 
 Our study showed that anti-infectives, anti-epileptics, and 
NSAIDs are the most commonly prescribed drugs for the spon-
taneously reported hepatic ADRs in Korea. Careful monitoring 
for drug-induced ADRs is needed for tuberculosis, pneumonia, 
intracranial injuries, and HIV infections. As this study is based 
on the spontaneous reporting program, it may contribute to the 
recognition of the general aspects of hepatic ADRs occurred in 
hospitals of Korea.
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